Bridging traditional botanical pharmacology and global regulatory compliance. We provide full-lifecycle OEM/ODM clinical trial design, bioanalytical validation, and cGMP-grade manufacturing under stringent ICH and GCP frameworks.
End-to-end preclinical profiling, active screening, and multi-phase clinical trial management optimized for worldwide pharmaceutical and nutraceutical authorizations.
Unlike single-molecule chemical entities, botanical candidates involve intricate multi-component matrices. Our ODM clinical trial solutions deliver reproducible molecular fingerprints and pharmacodynamic validation across dynamic human cohorts.
Overcoming batch inconsistencies through chromatographic fingerprinting (HPTLC, HPLC-MS, GC). We establish molecular benchmarks before Phase I escalation to satisfy global pharmacopeial standards.
GLP-compliant toxicology workflows: LD50 assessments, acute and chronic toxicity profiling, and in vitro Ames/genotoxicity tests that mitigate regulatory hold times during Investigational New Drug (IND) reviews.
Utilizing validated animal models of metabolic disorders, inflammatory cascades, and neuroprotection to generate definitive biomarkers that inform human dose escalation strategies.
Regional authorities enforce distinct evidentiary thresholds. MedGence crafts tailored study protocols meeting clinical, commercial, and geographical registration requirements.
Small-group human intervention trials targeting North American FTC/FDA substantiation criteria and European EFSA Article 13.1 health claim verifications, quantifying subjective metrics via objective blood biomarkers.
Double-blind, placebo-controlled human skin barrier, hyperpigmentation, and anti-photoaging evaluations conducted via TEWL, chromameter mapping, and 3D surface profilometry in specific demographic populations.
Rigorous Phase I safety/tolerability and Phase II/III randomized multicenter trials designed to register clinical hospital preparations (over 56 approved to date) and botanical new drug candidates with NMPA and FDA centers.
Integrating artificial intelligence, multi-omics, and decentralized data capture to accelerate clinical endpoints for complex biological substances.
In silico molecular docking and network pharmacology modeling predict synergy among multi-herb TCM mixtures, isolating target pathways (e.g., AMPK, NF-kB) prior to clinical initiation.
Employing high-resolution LC-MS/MS untargeted metabolomics on subject plasma to characterize how diverse metabolic phenotypes process botanical polyphenols, unlocking precision nutrition models.
Leveraging remote patient monitoring, wearable physiological sensors, and digital ePRO diaries to expand cohort retention, reduce geographic bias, and capture real-time real-world evidence (RWE).
Combining primary agro-botanical hubs with modern industrial extraction and high-capacity cGMP dosage manufacturing creates unrivaled speed-to-market advantages.
Direct linkage with wild-crafted and GAP-certified cultivation regions in China. We catalog geographic variations in secondary metabolites to pinpoint the peak seasonal potency of botanical actives.
Avoid the friction of third-party tech transfers. Our Changsha analytical center feeds data directly into self-owned and managed pilot facilities, guaranteeing smooth scale-up to metric-ton outputs.
By conducting preclinical studies and multicenter clinical phases in qualified Chinese medical centers, sponsors realize significant operational efficiencies without sacrificing protocol rigor or ICH alignment.
Every trial dossier is engineered from inception to withstand regulatory reviews across key international agencies.
Human trials run in accordance with ICH E6(R2) standards, ensuring ethical Institutional Review Board (IRB) reviews, strict informed consent, and transparent clinical trial registry postings.
All clinical endpoints are gathered using validated Electronic Data Capture (EDC) systems equipped with immutable audit trails, electronic signatures, and tamper-evident data management protocols.
Our pilot plants compound, package, code, and randomize clinical supply batches under cGMP conditions, ensuring double-blind placebo integrity and real-time stability monitoring.
Transition validated research directly into commercial formulations across oral liquids, hard capsules, softgels, micro-tablets, and functional granules.
Essential guidance for clinical investigators, sourcing executives, and regulatory managers scoping natural medicine research partnerships.
